{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T02:49:50Z","timestamp":1785898190348,"version":"3.56.0"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T00:00:00Z","timestamp":1648425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T00:00:00Z","timestamp":1648425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-022-00808-1","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T05:19:53Z","timestamp":1648531193000},"page":"255-272","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["The wide spectrum of cryoglobulinemic vasculitis and an overview of therapeutic advancements"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2149-5471","authenticated-orcid":false,"given":"Franco","family":"Dammacco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Lauletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Vacca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,28]]},"reference":[{"issue":"4","key":"808_CR1","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1097\/00000441-194710000-00009","volume":"214","author":"AB Lerner","year":"1947","unstructured":"Lerner AB, Watson CJ. Studies of cryoglobulins; unusual purpura associated with the presence of a high concentration of cryoglobulin (cold precipitable serum globulin). Am J Med Sci. 1947;214(4):410\u20135.","journal-title":"Am J Med Sci"},{"issue":"5","key":"808_CR2","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/0002-9343(74)90852-3","volume":"57","author":"JC Brouet","year":"1974","unstructured":"Brouet JC, Clauvel JP, Danon F, Klein M, Seligmann M. Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med. 1974;57(5):775\u201388.","journal-title":"Am J Med"},{"issue":"1","key":"808_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41572-018-0009-4","volume":"4","author":"D Roccatello","year":"2018","unstructured":"Roccatello D, Saadoun D, Ramos-Casals M, et al. Cryoglobulinaemia. Nat Rev Dis Primers. 2018;4(1):11.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"808_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10238-018-0536-z","volume":"19","author":"F Dammacco","year":"2019","unstructured":"Dammacco F, Lauletta G, Russi S. Clinical practice: hepatitis C virus infection, cryoglobulinemia and cryoglobulinemic vasculitis. Clin Exp Med. 2019;19(1):1\u201321.","journal-title":"Clin Exp Med"},{"issue":"2","key":"808_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/MD.0b013e318288925c","volume":"92","author":"B Terrier","year":"2013","unstructured":"Terrier B, Karras A, Kahn JE, et al. The spectrum of type I cryoglobulinemia vasculitis: new insights based on 64 cases. Medicine (Baltimore). 2013;92(2):61\u20138.","journal-title":"Medicine (Baltimore)"},{"issue":"7","key":"808_CR6","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/ajh.24745","volume":"92","author":"S Sidana","year":"2017","unstructured":"Sidana S, Rajkumar SV, Dispenzieri A, et al. Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia. Am J Hematol. 2017;92(7):668\u201373.","journal-title":"Am J Hematol"},{"issue":"6","key":"808_CR7","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/0002-9343(66)90199-9","volume":"40","author":"M Meltzer","year":"1966","unstructured":"Meltzer M, Franklin EC. Cryoglobulinemia\u2013a study of twenty-nine patients I IgG and IgM cryoglobulins and factors affecting cryoprecipitability. Am J Med. 1966;40(6):828\u201336.","journal-title":"Am J Med"},{"issue":"6","key":"808_CR8","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/BF01726453","volume":"19","author":"C Ferri","year":"1991","unstructured":"Ferri C, Greco F, Longombardo G, et al. Antibodies against hepatitis C virus in mixed cryoglobulinemia patients. Infection. 1991;19(6):417\u201320.","journal-title":"Infection"},{"issue":"21","key":"808_CR9","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1056\/NEJM199211193272104","volume":"327","author":"V Agnello","year":"1992","unstructured":"Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med. 1992;327(21):1490\u20135.","journal-title":"N Engl J Med"},{"issue":"3","key":"808_CR10","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/j.1365-2249.1992.tb03001.x","volume":"87","author":"F Dammacco","year":"1992","unstructured":"Dammacco F, Sansonno D. Antibodies to hepatitis C virus in essential mixed cryoglobulinaemia. Clin Exp Immunol. 1992;87(3):352\u20136.","journal-title":"Clin Exp Immunol"},{"key":"808_CR11","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jaut.2015.08.008","volume":"65","author":"B Terrier","year":"2015","unstructured":"Terrier B, Marie I, Lacraz A, et al. Non HCV-related infectious cryoglobulinemia vasculitis: results from the French nationwide CryoVas survey and systematic review of the literature. J Autoimmun. 2015;65:74\u201381.","journal-title":"J Autoimmun"},{"issue":"1","key":"808_CR12","first-page":"67","volume":"35 Suppl 103","author":"M Galli","year":"2017","unstructured":"Galli M, Oreni L, Saccardo F, et al. HCV-unrelated cryoglobulinaemic vasculitis: the results of a prospective observational study by the Italian Group for the Study of Cryoglobulinaemias (GISC). Clin Exp Rheumatol. 2017;35 Suppl 103(1):67\u201376.","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"808_CR13","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.dld.2016.03.018","volume":"48","author":"C Mazzaro","year":"2016","unstructured":"Mazzaro C, Dal Maso L, Urraro T, et al. Hepatitis B virus related cryoglobulinemic vasculitis: a multicentre open label study from the Gruppo Italiano di Studio delle Crioglobulinemie - GISC. Dig Liver Dis. 2016;48(7):780\u20134.","journal-title":"Dig Liver Dis"},{"issue":"3","key":"808_CR14","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1093\/gastro\/gox021","volume":"5","author":"F Bazerbachi","year":"2017","unstructured":"Bazerbachi F, Leise MD, Watt KD, Murad MH, Prokop LJ, Haffar S. Systematic review of mixed cryoglobulinemia associated with hepatitis E virus infection: association or causation? Gastroenterol Rep (Oxf). 2017;5(3):178\u201384.","journal-title":"Gastroenterol Rep (Oxf)"},{"issue":"10","key":"808_CR15","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1002\/jmv.20695","volume":"78","author":"N Kosmas","year":"2006","unstructured":"Kosmas N, Kontos A, Panayiotakopoulos G, Dimitrakopoulos A, Kordossis T. Decreased prevalence of mixed cryoglobulinemia in the HAART era among HIV-positive, HCV-negative patients. J Med Virol. 2006;78(10):1257\u201361.","journal-title":"J Med Virol"},{"issue":"7","key":"808_CR16","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1053\/j.gastro.2013.02.039","volume":"144","author":"J Chen","year":"2013","unstructured":"Chen J, Florian J, Carter W, et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology. 2013;144(7):1450-1455.e2.","journal-title":"Gastroenterology"},{"issue":"10179","key":"808_CR17","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","volume":"393","author":"F Carrat","year":"2019","unstructured":"Carrat F, Fontaine H, Dorival C, French ANRS CO22 Hepather cohort, et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting anti-viral treatment: a prospective cohort study. Lancet. 2019;393(10179):1453\u201364.","journal-title":"Lancet"},{"issue":"24","key":"808_CR18","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1001\/jama.2012.144878","volume":"308","author":"AJ van der Meer","year":"2012","unstructured":"van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584\u201393.","journal-title":"JAMA"},{"issue":"1","key":"808_CR19","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/hep.30823","volume":"71","author":"F Kanwal","year":"2020","unstructured":"Kanwal F, Kramer JR, Asch SM, Cao Y, Li L, El-Serag HB. Long-term risk of hepatocellular carcinoma in HCV patients treated with direct acting anti-viral agents. Hepatology. 2020;71(1):44\u201355.","journal-title":"Hepatology"},{"issue":"3","key":"808_CR20","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1136\/gutjnl-2017-313983","volume":"67","author":"P Mahale","year":"2018","unstructured":"Mahale P, Engels EA, Li R, et al. The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection. Gut. 2018;67(3):553\u201361.","journal-title":"Gut"},{"issue":"27","key":"808_CR21","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","volume":"373","author":"JJ Feld","year":"2015","unstructured":"Feld JJ, Jacobson IM, H\u00e9zode C, ASTRAL-1 Investigators, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373(27):2599\u2013607.","journal-title":"N Engl J Med"},{"issue":"27","key":"808_CR22","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","volume":"373","author":"GR Foster","year":"2015","unstructured":"Foster GR, Afdhal N, Roberts SK, ASTRAL-2 Investigators; ASTRAL-3 Investigators, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373(27):2608\u201317.","journal-title":"N Engl J Med"},{"issue":"10","key":"808_CR23","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1136\/annrheumdis-2015-208339","volume":"75","author":"D Saadoun","year":"2016","unstructured":"Saadoun D, Thibault V, Si Ahmed SN, et al. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Ann Rheum Dis. 2016;75(10):1777\u201382.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"808_CR24","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/hep.28297","volume":"63","author":"ME Sise","year":"2016","unstructured":"Sise ME, Bloom AK, Wisocky J, et al. Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting anti-viral agents. Hepatology. 2016;63(2):408\u201317.","journal-title":"Hepatology"},{"issue":"5","key":"808_CR25","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1002\/hep.28753","volume":"64","author":"L Gragnani","year":"2016","unstructured":"Gragnani L, Visentini M, Fognani E, et al. Prospective study of guideline-tailored therapy with direct-acting anti-virals for hepatitis C virus-associated mixed cryoglobulinemia. Hepatology. 2016;64(5):1473\u201382.","journal-title":"Hepatology"},{"issue":"4","key":"808_CR26","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.cgh.2016.09.158","volume":"15","author":"M Bonacci","year":"2017","unstructured":"Bonacci M, Lens S, Londo\u00f1o MC, et al. Virologic, clinical, and immune response outcomes of patients with hepatitis C virus-associated cryoglobulinemia treated with direct-acting anti-virals. Clin Gastroenterol Hepatol. 2017;15(4):575-583.e1.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"808_CR27","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13075-017-1280-6","volume":"19","author":"G Lauletta","year":"2017","unstructured":"Lauletta G, Russi S, Pavone F, Vacca A, Dammacco F. Direct-acting anti-viral agents in the therapy of hepatitis C virus-related mixed cryoglobulinaemia: a single-centre experience. Arthritis Res Ther. 2017;19(1):74.","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"808_CR28","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1038\/ajg.2017.49","volume":"112","author":"JS Emery","year":"2017","unstructured":"Emery JS, Kuczynski M, La D, et al. Efficacy and safety of direct acting anti-virals for the treatment of mixed cryoglobulinemia. Am J Gastroenterol. 2017;112(8):1298\u2013308.","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"808_CR29","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1038\/ajg.2017.294","volume":"112","author":"S Sollima","year":"2017","unstructured":"Sollima S, Milazzo L, Antinori S, Galli M. Direct-acting anti-virals and mixed cryoglobulinemia vasculitis: long-term outcome of patients achieving HCV eradication. Am J Gastroenterol. 2017;112(11):1753\u20134.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"808_CR30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1053\/j.gastro.2017.03.006","volume":"153","author":"D Saadoun","year":"2017","unstructured":"Saadoun D, Pol S, Ferfar Y, et al. Efficacy and safety of sofosbuvir plus daclatasvir for treatment of HCV-associated cryoglobulinemia vasculitis. Gastroenterology. 2017;153(1):49-52.e5.","journal-title":"Gastroenterology"},{"issue":"3","key":"808_CR31","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.cgh.2018.05.021","volume":"17","author":"P Cacoub","year":"2019","unstructured":"Cacoub P, Si Ahmed SN, Ferfar Y, et al. Long-term efficacy of interferon-free anti-viral treatment regimens in patients with hepatitis C virus-associated cryoglobulinemia vasculitis. Clin Gastroenterol Hepatol. 2019;17(3):518\u201326.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"808_CR32","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/apt.14845","volume":"48","author":"L Gragnani","year":"2018","unstructured":"Gragnani L, Cerretelli G, Lorini S, et al. Interferon-free therapy in hepatitis C virus mixed cryoglobulinaemia: a prospective, controlled, clinical and quality of life analysis. Aliment Pharmacol Ther. 2018;48(4):440\u201350.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"808_CR33","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1053\/j.gastro.2018.04.024","volume":"155","author":"M Bonacci","year":"2018","unstructured":"Bonacci M, Lens S, Mari\u00f1o Z, et al. Long-term outcomes of patients with HCV-associated cryoglobulinemic vasculitis after virologic cure. Gastroenterology. 2018;155(2):311-315.e6.","journal-title":"Gastroenterology"},{"issue":"2","key":"808_CR34","first-page":"107","volume":"36 Suppl 111","author":"C Mazzaro","year":"2018","unstructured":"Mazzaro C, Dal Maso L, Quartuccio L, et al. Long-term effects of the new direct anti-viral agents (DAAs) therapy for HCV-related mixed cryoglobulinaemia without renal involvement: a multicentre open-label study. Clin Exp Rheumatol. 2018;36 Suppl 111(2):107\u201314.","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"808_CR35","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/liv.14053","volume":"39","author":"M Visentini","year":"2019","unstructured":"Visentini M, Del Padre M, Colantuono S, et al. Long-lasting persistence of large B-cell clones in hepatitis C virus-cured patients with complete response of mixed cryoglobulinaemia vasculitis. Liver Int. 2019;39(4):628\u201332.","journal-title":"Liver Int"},{"issue":"11","key":"808_CR36","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1111\/apt.15240","volume":"49","author":"HB El-Serag","year":"2019","unstructured":"El-Serag HB, Christie IC, Puenpatom A, Castillo D, Kanwal F, Kramer JR. The effects of sustained virological response to direct-acting anti-viral therapy on the risk of extrahepatic manifestations of hepatitis C infection. Aliment Pharmacol Ther. 2019;49(11):1442\u20137.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"808_CR37","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1111\/bjh.17036","volume":"191","author":"G Pozzato","year":"2020","unstructured":"Pozzato G, Mazzaro C, Artemova M, et al. Direct-acting anti-viral agents for hepatitis C virus-mixed cryoglobulinaemia: dissociated virological and haematological responses. Br J Haematol. 2020;191(5):775\u201383.","journal-title":"Br J Haematol"},{"issue":"9","key":"808_CR38","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1055\/a-1217-7669","volume":"58","author":"J Vermehren","year":"2020","unstructured":"Vermehren J, Serfert Y, Cornberg M, et al. Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting anti-viral therapy for chronic hepatitis C: results from the German Hepatitis C-Registry (DHC-R). Z Gastroenterol. 2020;58(9):841\u20136.","journal-title":"Z Gastroenterol"},{"issue":"5","key":"808_CR39","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","volume":"73","author":"European Association for the Study of the Liver","year":"2020","unstructured":"European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: final update of the series\u2606. J Hepatol. 2020;73(5):1170\u2013218.","journal-title":"J Hepatol"},{"issue":"12","key":"808_CR40","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.autrev.2016.09.006","volume":"15","author":"C Ferri","year":"2016","unstructured":"Ferri C, Ramos-Casals M, Zignego AL, ISG-EHCV coauthors, et al. International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. Autoimmun Rev. 2016;15(12):1145\u201360.","journal-title":"Autoimmun Rev"},{"issue":"8","key":"808_CR41","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.autrev.2011.01.008","volume":"10","author":"M Pietrogrande","year":"2011","unstructured":"Pietrogrande M, De Vita S, Zignego AL, et al. Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmun Rev. 2011;10(8):444\u201354.","journal-title":"Autoimmun Rev"},{"issue":"11","key":"808_CR42","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1056\/NEJMra1208642","volume":"369","author":"F Dammacco","year":"2013","unstructured":"Dammacco F, Sansonno D. Therapy for hepatitis C virus-related cryoglobulinemic vasculitis. N Engl J Med. 2013;369(11):1035\u201345.","journal-title":"N Engl J Med"},{"issue":"8","key":"808_CR43","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.autrev.2019.06.008","volume":"18","author":"M Galli","year":"2019","unstructured":"Galli M, Monti G, Marson P, et al. Recommendations for managing the manifestations of severe and life-threatening mixed cryoglobulinemia syndrome. Autoimmun Rev. 2019;18(8):778\u201385.","journal-title":"Autoimmun Rev"},{"issue":"4","key":"808_CR44","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S1473-3099(05)70053-0","volume":"5","author":"D Sansonno","year":"2005","unstructured":"Sansonno D, Dammacco F. Hepatitis C virus, cryoglobulinaemia, and vasculitis: immune complex relations. Lancet Infect Dis. 2005;5(4):227\u201336.","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"808_CR45","doi-asserted-by":"publisher","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","volume":"150","author":"K de Groot","year":"2009","unstructured":"de Groot K, Harper L, Jayne DR, EUVAS (European Vasculitis Study Group), et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009;150(10):670\u201380.","journal-title":"Ann Intern Med"},{"issue":"10","key":"808_CR46","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.1182\/blood-2002-10-3162","volume":"101","author":"D Sansonno","year":"2003","unstructured":"Sansonno D, De Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood. 2003;101(10):3818\u201326.","journal-title":"Blood"},{"issue":"3","key":"808_CR47","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1182\/blood-2009-10-245878","volume":"116","author":"F Dammacco","year":"2010","unstructured":"Dammacco F, Tucci FA, Lauletta G, et al. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood. 2010;116(3):343\u201353.","journal-title":"Blood"},{"issue":"1","key":"808_CR48","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.autrev.2011.07.005","volume":"11","author":"C Ferri","year":"2011","unstructured":"Ferri C, Cacoub P, Mazzaro C, et al. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. Autoimmun Rev. 2011;11(1):48\u201355.","journal-title":"Autoimmun Rev"},{"issue":"3","key":"808_CR49","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1002\/art.34331","volume":"64","author":"S De Vita","year":"2012","unstructured":"De Vita S, Quartuccio L, Isola M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64(3):843\u201353.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"808_CR50","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.autrev.2011.04.033","volume":"10","author":"M Visentini","year":"2011","unstructured":"Visentini M, Ludovisi S, Petrarca A, et al. A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection. Autoimmun Rev. 2011;10(11):714\u20139.","journal-title":"Autoimmun Rev"},{"issue":"12","key":"808_CR51","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.1002\/art.25000","volume":"60","author":"D S\u00e8ne","year":"2009","unstructured":"S\u00e8ne D, Ghillani-Dalbin P, Amoura Z, Musset L, Cacoub P. Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. Arthritis Rheum. 2009;60(12):3848\u201355.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"808_CR52","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1136\/ard.2010.144998","volume":"70","author":"MH Buch","year":"2011","unstructured":"Buch MH, Smolen JS, Betteridge N, Rituximab Consensus Expert Committee, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(6):909\u201320.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"808_CR53","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1182\/blood-2006-08-041525","volume":"109","author":"G Lake-Bakaar","year":"2007","unstructured":"Lake-Bakaar G, Dustin L, McKeating J, Newton K, Freeman V, Frost SD. Hepatitis C virus and alanine aminotransferase kinetics following B-lymphocyte depletion with rituximab: evidence for a significant role of humoral immunity in the control of viremia in chronic HCV liver disease. Blood. 2007;109(2):845\u20136.","journal-title":"Blood"},{"issue":"3","key":"808_CR54","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1182\/blood-2009-11-253948","volume":"116","author":"A Petrarca","year":"2010","unstructured":"Petrarca A, Rigacci L, Caini P, et al. Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. Blood. 2010;116(3):335\u201342.","journal-title":"Blood"},{"issue":"3","key":"808_CR55","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1182\/blood-2009-10-248518","volume":"116","author":"D Saadoun","year":"2010","unstructured":"Saadoun D, Resche Rigon M, Sene D, et al. Rituximab plus Peg-interferon-alpha\/ribavirin compared with Peg-interferon-alpha\/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood. 2010;116(3):326\u201334.","journal-title":"Blood"},{"issue":"3","key":"808_CR56","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1002\/art.34322","volume":"64","author":"MC Sneller","year":"2012","unstructured":"Sneller MC, Hu Z, Langford CA. A randomized controlled trial of rituximab following failure of anti-viral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64(3):835\u201342.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"808_CR57","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.jhep.2017.02.010","volume":"66","author":"M Ramos-Casals","year":"2017","unstructured":"Ramos-Casals M, Zignego AL, Ferri C, International Study Group of Extrahepatic Manifestations related to HCV (ISG-EHCV), et al. Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. J Hepatol. 2017;66(6):1282\u201399.","journal-title":"J Hepatol"},{"issue":"15","key":"808_CR58","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1182\/bloodadvances.2021004295","volume":"5","author":"M Brink","year":"2021","unstructured":"Brink M, Kahle XU, Vermaat JSP, et al. Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study. Blood Adv. 2021;5(15):2958\u201364.","journal-title":"Blood Adv"},{"issue":"1","key":"808_CR59","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s11739-020-02386-0","volume":"16","author":"C Vacchi","year":"2021","unstructured":"Vacchi C, Visentini M, Gragnani L, et al. Safety and effectiveness of biosimilar of Rituximab CT-P10 in the treatment of cryoglobulinemic vasculitis: the MARBLe study (Mixed cryoglobulinemiA Rituximab BiosimiLar). Intern Emerg Med. 2021;16(1):149\u201356.","journal-title":"Intern Emerg Med"},{"issue":"3","key":"808_CR60","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1136\/ard.2007.085910","volume":"68","author":"DA Landau","year":"2009","unstructured":"Landau DA, Rosenzwajg M, Saadoun D, Klatzmann D, Cacoub P. The B lymphocyte stimulator receptor-ligand system in hepatitis C virus-induced B cell clonal disorders. Ann Rheum Dis. 2009;68(3):337\u201344.","journal-title":"Ann Rheum Dis"},{"key":"808_CR61","doi-asserted-by":"publisher","first-page":"102577","DOI":"10.1016\/j.jaut.2020.102577","volume":"116","author":"D Saadoun","year":"2021","unstructured":"Saadoun D, Ghembaza A, Riviere S, et al. Rituximab plus belimumab in non-infectious refractory cryoglobulinemia vasculitis: a pilot study. J Autoimmun. 2021;116:102577.","journal-title":"J Autoimmun"},{"issue":"4","key":"808_CR62","doi-asserted-by":"publisher","first-page":"103034","DOI":"10.1016\/j.autrev.2022.103034","volume":"21","author":"C Pouchelon","year":"2022","unstructured":"Pouchelon C, Visentini M, Emmi G, et al. Management of nonviral mixed cryoglobulinemia vasculitis refractory to rituximab: data from a European collaborative study and review of the literature. Autoimmun Rev. 2022;21(4):103034.","journal-title":"Autoimmun Rev"},{"issue":"9","key":"808_CR63","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1136\/annrheumdis-2020-217481","volume":"79","author":"K Chevalier","year":"2020","unstructured":"Chevalier K, Belkhir R, Seror R, Mariette X, Nocturne G. Efficacity of a sequential treatment by anti-CD 20 monoclonal antibody and belimumab in type II cryoglobulinaemia associated with primary Sj\u00f6gren syndrome refractory to rituximab alone. Ann Rheum Dis. 2020;79(9):1257\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"808_CR64","first-page":"149","volume":"31","author":"J Schwartz","year":"2016","unstructured":"Schwartz J, Padmanabhan A, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the seventh special issue guidelines on the use of therapeutic apheresis. J Clin Apher. 2016;31(3):149\u201362.","journal-title":"J Clin Apher"},{"issue":"9813","key":"808_CR65","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/S0140-6736(11)60242-0","volume":"379","author":"M Ramos-Casals","year":"2012","unstructured":"Ramos-Casals M, Stone JH, Cid MC, Bosch X. The cryoglobulinaemias. Lancet. 2012;379(9813):348\u201360.","journal-title":"Lancet"},{"issue":"5","key":"808_CR66","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.transci.2018.06.005","volume":"57","author":"P Marson","year":"2018","unstructured":"Marson P, Monti G, Montani F, et al. Apheresis treatment of cryoglobulinemic vasculitis: a multicentre cohort study of 159 patients. Transfus Apher Sci. 2018;57(5):639\u201345.","journal-title":"Transfus Apher Sci"},{"issue":"11","key":"808_CR67","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.3390\/cancers13112625","volume":"13","author":"Y Hatano","year":"2021","unstructured":"Hatano Y, Ideta T, Hirata A, et al. Virus-driven carcinogenesis. Cancers (Basel). 2021;13(11):2625.","journal-title":"Cancers (Basel)"},{"issue":"5\u20136","key":"808_CR68","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3109\/10428199809057606","volume":"31","author":"F Dammacco","year":"1998","unstructured":"Dammacco F, Gatti P, Sansonno D. Hepatitis C virus infection, mixed cryoglobulinemia, and non-Hodgkin\u2019s lymphoma: an emerging picture. Leuk Lymphoma. 1998;31(5\u20136):463\u201376.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"808_CR69","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.cgh.2008.02.011","volume":"6","author":"S de Sanjose","year":"2008","unstructured":"de Sanjose S, Benavente Y, Vajdic CM, et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol. 2008;6(4):451\u20138.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"808_CR70","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jhep.2013.03.018","volume":"59","author":"J Peveling-Oberhag","year":"2013","unstructured":"Peveling-Oberhag J, Arcaini L, Hansmann ML, Zeuzem S. Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. J Hepatol. 2013;59(1):169\u201377.","journal-title":"J Hepatol"},{"issue":"5","key":"808_CR71","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/MD.0b013e31829d2abc","volume":"92","author":"G Lauletta","year":"2013","unstructured":"Lauletta G, Russi S, Conteduca V, Sansonno L, Dammacco F, Sansonno D. Impact of cryoglobulinemic syndrome on the outcome of chronic hepatitis C virus infection: a 15-year prospective study. Medicine (Baltimore). 2013;92(5):245\u201356.","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"808_CR72","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1056\/NEJMoa013376","volume":"347","author":"O Hermine","year":"2002","unstructured":"Hermine O, Lefr\u00e8re F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med. 2002;347(2):89\u201394.","journal-title":"N Engl J Med"},{"issue":"21","key":"808_CR73","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1182\/blood-2016-05-714667","volume":"128","author":"L Arcaini","year":"2016","unstructured":"Arcaini L, Besson C, Frigeni M, et al. Interferon-free anti-viral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. Blood. 2016;128(21):2527\u201332.","journal-title":"Blood"},{"key":"808_CR74","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1111\/liv.14119","volume":"39","author":"M Masarone","year":"2019","unstructured":"Masarone M, Persico M. Hepatitis C virus infection and non-hepatocellular malignancies in the DAA era: a systematic review and meta-analysis. Liver Int. 2019;39:1292\u2013306.","journal-title":"Liver Int"},{"issue":"5","key":"808_CR75","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1038\/s41375-019-0687-2","volume":"34","author":"M Frigeni","year":"2020","unstructured":"Frigeni M, Besson C, Visco C, et al. Interferon-free compared to interferon-based anti-viral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection. Leukemia. 2020;34(5):1462\u20136.","journal-title":"Leukemia"},{"issue":"5","key":"808_CR76","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.autrev.2017.03.004","volume":"16","author":"AL Zignego","year":"2017","unstructured":"Zignego AL, Ramos-Casals M, Ferri C, ISG-EHCV, et al. International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. Autoimmun Rev. 2017;16(5):523\u201341.","journal-title":"Autoimmun Rev"},{"issue":"5","key":"808_CR77","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1111\/bjh.13196","volume":"168","author":"S Harel","year":"2015","unstructured":"Harel S, Mohr M, Jahn I, et al. Clinico-biological characteristics and treatment of type I monoclonal cryoglobulinaemia: a study of 64 cases. Br J Haematol. 2015;168(5):671\u20138.","journal-title":"Br J Haematol"},{"issue":"3","key":"808_CR78","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1182\/blood-2016-09-719773","volume":"129","author":"E Muchtar","year":"2017","unstructured":"Muchtar E, Magen H, Gertz MA. How I treat cryoglobulinemia. Blood. 2017;129(3):289\u201398.","journal-title":"Blood"},{"key":"808_CR79","first-page":"1","volume":"16","author":"R Dammacco","year":"2021","unstructured":"Dammacco R, Lisch W, Kivel\u00e4 TT, et al. the spectrum of ocular manifestations in patients with Waldenstr\u00f6m\u2019s macroglobulinemia. Ocul Immunol Inflamm. 2021;16:1\u201310.","journal-title":"Ocul Immunol Inflamm"},{"issue":"2","key":"808_CR80","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41408-021-00432-4","volume":"11","author":"E Terpos","year":"2021","unstructured":"Terpos E, Mikhael J, Hajek R, et al. Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. Blood Cancer J. 2021;11(2):40.","journal-title":"Blood Cancer J"},{"issue":"3","key":"808_CR81","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S1470-2045(20)30756-7","volume":"22","author":"P Moreau","year":"2021","unstructured":"Moreau P, Kumar SK, San Miguel J, et al. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021;22(3):e105\u201318.","journal-title":"Lancet Oncol"},{"issue":"9","key":"808_CR82","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1056\/NEJMoa1200710","volume":"367","author":"SP Treon","year":"2012","unstructured":"Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenstr\u00f6m\u2019s macroglobulinemia. N Engl J Med. 2012;367(9):826\u201333.","journal-title":"N Engl J Med"},{"issue":"11","key":"808_CR83","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1182\/blood-2013-09-525808","volume":"123","author":"ZR Hunter","year":"2014","unstructured":"Hunter ZR, Xu L, Yang G, et al. The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood. 2014;123(11):1637\u201346.","journal-title":"Blood"},{"issue":"11","key":"808_CR84","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1200\/JCO.19.02314","volume":"38","author":"SP Treon","year":"2020","unstructured":"Treon SP, Xu L, Guerrera ML, et al. Genomic landscape of Waldenstr\u00f6m macroglobulinemia and its impact on treatment strategies. J Clin Oncol. 2020;38(11):1198\u2013208.","journal-title":"J Clin Oncol"},{"issue":"2","key":"808_CR85","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41375-021-01417-9","volume":"36","author":"JJ Castillo","year":"2022","unstructured":"Castillo JJ, Meid K, Gustine JN, et al. Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia. Leukemia. 2022;36(2):532\u20139.","journal-title":"Leukemia"},{"issue":"10","key":"808_CR86","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s11864-021-00890-9","volume":"22","author":"S Sarosiek","year":"2021","unstructured":"Sarosiek S, Treon SP, Castillo JJ. How to sequence therapies in Waldenstr\u00f6m macroglobulinemia. Curr Treat Options Oncol. 2021;22(10):92.","journal-title":"Curr Treat Options Oncol"},{"issue":"9","key":"808_CR87","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1080\/14740338.2021.1945031","volume":"20","author":"M Migkou","year":"2021","unstructured":"Migkou M, Fotiou D, Gavriatopoulou M, Dimopoulos MA. Ibrutinib plus rituximab for the treatment of adult patients with Waldenstr\u00f6m\u2019s macroglobulinemia: a safety evaluation. Expert Opin Drug Saf. 2021;20(9):987\u201395.","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"808_CR88","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/bjh.13794","volume":"174","author":"JJ Castillo","year":"2016","unstructured":"Castillo JJ, Kanan S, Meid K, Manning R, Hunter ZR, Treon SP. Rituximab intolerance in patients with Waldenstr\u00f6m macroglobulinaemia. Br J Haematol. 2016;174(4):645\u20138.","journal-title":"Br J Haematol"},{"issue":"2","key":"808_CR89","doi-asserted-by":"publisher","first-page":"162","DOI":"10.23736\/S0026-4806.20.07076-7","volume":"112","author":"D Rossi","year":"2021","unstructured":"Rossi D, Sciascia S, Fenoglio R, et al. Cryoglobulinemic glomerulonephritis: clinical presentation and histological features, diagnostic pitfalls and controversies in the management. State of the art and the experience on a large monocentric cohort treated with B cell depletion therapy. Minerva Med. 2021;112(2):162\u201374.","journal-title":"Minerva Med"},{"issue":"2","key":"808_CR90","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/sdi.12759","volume":"32","author":"JB Henson","year":"2019","unstructured":"Henson JB, Sise ME. The association of hepatitis C infection with the onset of CKD and progression into ESRD. Semin Dial. 2019;32(2):108\u201318.","journal-title":"Semin Dial"},{"issue":"15","key":"808_CR91","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","volume":"377","author":"E Gane","year":"2017","unstructured":"Gane E, Lawitz E, Pugatch D, et al. Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med. 2017;377(15):1448\u201355.","journal-title":"N Engl J Med"},{"issue":"10003","key":"808_CR92","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","volume":"386","author":"D Roth","year":"2015","unstructured":"Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4\u20135 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386(10003):1537\u201345.","journal-title":"Lancet"},{"issue":"3","key":"808_CR93","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.bpg.2017.04.012","volume":"31","author":"MG Ghany","year":"2017","unstructured":"Ghany MG. Current treatment guidelines of chronic hepatitis B: the role of nucleos(t)ide analogues and peginterferon. Best Pract Res Clin Gastroenterol. 2017;31(3):299\u2013309.","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"4","key":"808_CR94","doi-asserted-by":"publisher","first-page":"56","DOI":"10.4292\/wjgpt.v12.i4.56","volume":"12","author":"NJ Shah","year":"2021","unstructured":"Shah NJ, Aloysius MM, Sharma NR, Pallav K. Advances in treatment and prevention of hepatitis B. World J Gastrointest Pharmacol Ther. 2021;12(4):56\u201378.","journal-title":"World J Gastrointest Pharmacol Ther"},{"issue":"1","key":"808_CR95","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","volume":"57","author":"European Association For The Study Of The Liver","year":"2012","unstructured":"European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):167\u201385.","journal-title":"J Hepatol"},{"issue":"25","key":"808_CR96","doi-asserted-by":"publisher","first-page":"5996","DOI":"10.1182\/blood-2011-12-396028","volume":"119","author":"B Terrier","year":"2012","unstructured":"Terrier B, Krastinova E, Marie I, et al. Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey. Blood. 2012;119(25):5996\u20136004.","journal-title":"Blood"},{"issue":"5","key":"808_CR97","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.semarthrit.2020.07.013","volume":"50","author":"OD Argyropoulou","year":"2020","unstructured":"Argyropoulou OD, Pezoulas V, Chatzis L, et al. Cryoglobulinemic vasculitis in primary Sj\u00f6gren\u2019s syndrome: clinical presentation, association with lymphoma and comparison with hepatitis C-related disease. Semin Arthritis Rheum. 2020;50(5):846\u201353.","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"808_CR98","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1097\/00005792-200107000-00004","volume":"80","author":"O Trejo","year":"2001","unstructured":"Trejo O, Ramos-Casals M, Garc\u00eda-Carrasco M, et al. Cryoglobulinemia: study of etiologic factors and clinical and immunologic features in 443 patients from a single center. Medicine (Baltimore). 2001;80(4):252\u201362.","journal-title":"Medicine (Baltimore)"},{"issue":"19","key":"808_CR99","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1001\/archinte.166.19.2101","volume":"166","author":"D Saadoun","year":"2006","unstructured":"Saadoun D, Sellam J, Ghillani-Dalbin P, Crecel R, Piette JC, Cacoub P. Increased risks of lymphoma and death among patients with non-hepatitis C virus-related mixed cryoglobulinemia. Arch Intern Med. 2006;166(19):2101\u20138.","journal-title":"Arch Intern Med"},{"issue":"4","key":"808_CR100","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.semarthrit.2020.05.004","volume":"50","author":"G Boleto","year":"2020","unstructured":"Boleto G, Ghillani-Dalbin P, Musset L, et al. Cryoglobulinemia after the era of chronic hepatitis C infection. Semin Arthritis Rheum. 2020;50(4):695\u2013700.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"808_CR101","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","volume":"79","author":"V Furer","year":"2020","unstructured":"Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(1):39\u201352.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"808_CR102","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1136\/annrheumdis-2021-221244","volume":"80","author":"MA Friedman","year":"2021","unstructured":"Friedman MA, Curtis JR, Winthrop KL. Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2021;80(10):1255\u201365.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"808_CR103","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1080\/14760584.2018.1495565","volume":"17","author":"N Lecrenier","year":"2018","unstructured":"Lecrenier N, Beukelaers P, Colindres R, et al. Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention. Expert Rev Vaccines. 2018;17(7):619\u201334.","journal-title":"Expert Rev Vaccines"},{"issue":"2","key":"808_CR104","doi-asserted-by":"publisher","first-page":"149","DOI":"10.55563\/clinexprheumatol\/2v6v5j","volume":"39 Suppl 129","author":"S Scarpato","year":"2021","unstructured":"Scarpato S, Sebastiani M, Quartuccio L, Italian Group for the Study of Cryoglobulinaemia (GISC), et al. Provisional recommendations for SARS-CoV-2 vaccination in patients with cryoglobulinaemic vasculitis. Clin Exp Rheumatol. 2021;39 Suppl 129(2):149\u201354.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"808_CR105","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/art.25033","volume":"62","author":"S van Assen","year":"2010","unstructured":"van Assen S, Holvast A, Benne CA, et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum. 2010;62(1):75\u201381.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"808_CR106","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3390\/vaccines9030203","volume":"9","author":"P Richi","year":"2021","unstructured":"Richi P, Yuste J, Nav\u00edo T, et al. Impact of biological therapies on the immune response after pneumococcal vaccination in patients with autoimmune inflammatory diseases. Vaccines (Basel). 2021;9(3):203.","journal-title":"Vaccines (Basel)"},{"key":"808_CR107","doi-asserted-by":"publisher","first-page":"102744","DOI":"10.1016\/j.jaut.2021.102744","volume":"125","author":"C Ferri","year":"2021","unstructured":"Ferri C, Ursini F, Gragnani L, et al. Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients\u2019 subgroups. J Autoimmun. 2021;125:102744.","journal-title":"J Autoimmun"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-022-00808-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-022-00808-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-022-00808-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T23:34:25Z","timestamp":1744155265000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-022-00808-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,28]]},"references-count":107,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["808"],"URL":"https:\/\/doi.org\/10.1007\/s10238-022-00808-1","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,28]]},"assertion":[{"value":"15 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}